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40 mg and rosuvastatin 5–10 mg (according to UK label). OBJECTIVES: To estimate 
the cost of treatment for achieving 1 % LDL-C reduction and the cost of getting a 
patient to LDL-C target of 2 mmol/L with ezetimibe co-administered with simvas-
tatin, compared to atorvastatin and rosuvastatin. METHODS: Following a 6-week 
run-in period on 40 mg simvastatin, patients were randomized to receive ezetimibe/
simvastatin 10/40 mg, atorvastatin 40 mg or rosuvastatin 5–10 mg for 6 weeks. The 
total treatment cost for the trial period was estimated. A post-hoc analysis of the trial 
participants was conducted to compare the treatment cost per patient achieving LDL-C 
target of 2 mmol/L between the three comparator treatments. The cost of generic 
simvastatin 40 mg was assumed to be £1.37 for a 28 day treatment (BNF). RESULTS: 
At the end of the 6 week trial period, the treatment cost per 1% reduction in LDL-C 
was estimated to be £1.58 (95% CI: £1.42–£1.79) for ezetimibe co-administered with 
simvastatin. The corresponding treatment costs were £3.33 (£2.64–£4.51) and £9.02 
(£4.59–£450.75) for atorvastatin and rosuvastatin, respectively. Cost per patient 
achieving the LDL-C target of 2 mmol/L was £61.49 (95% CI: £56.66–£67.22) for 
ezetimibe co-administered with simvastatin compared to £101.84 (£87.69–£121.42) 
for atorvastatin and £155.06 (£122.54–£211.12) for rosuvastatin. CONCLUSIONS: 
Co-administration of ezetimibe with simvastatin 40 mg is a cost efﬁcient way of 
reducing LDL-C compared to atorvastatin 40 mg or rosuvastatin 5–10 mg mono-
therapy regimen.
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OBJECTIVES: Antihypertensive therapy is a well-established approach to reducing 
the risk of cardiovascular disease (CVD). The main objective of this meta-analysis was 
to ﬁnd out whether the calcium channel blockers are superior, equal, or inferior to 
other treatments in reducing the frequency of cardiovascular complications. 
METHODS: Studies were identiﬁed through PubMed with a publication date before 
February 24, 2009. We selected studies in hypertension that assessed cardiovascular 
events and included at least 100 patients, who were randomly assigned calcium 
channel blockers or other antihypertensive drugs and who were followed up for at 
least 1 year. The 2 authors independently assessed studies for inclusion and quality. 
We extracted from source documents coronary heart disease, stroke, congestive heart 
failure, cardiovascular disease events, total mortality, cardiovascular disease mortality. 
RESULTS: The 16 eligible studies included 132,078 patients. Calcium channel block-
ers provided more protection against stroke than the conventional therapy consisting 
of diuretics and/or B-blockers (risk ratio 0.86, 95% CI 0.80~0.93) and new antihy-
pertensive drugs, such as angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers (risk ratio 0.87, 95% CI 0.79~0.96). There were no signiﬁcant dif-
ferences in major cardiovascular events risk, total mortality and cardiovascular disease 
mortality between regimens based on calcium channel blockers and regimens based 
on the conventional therapy (risk ratio 0.98, 95% CI 0.88~1.09; risk ratio 0.98, 95% 
CI 0.90~1.06; risk ratio 0.95, 95% CI 0.83~1.07) or new antihypertensive drugs (risk 
ratio 1.00, 95% CI 0.95~1.05; risk ratio 0.97, 95% CI 0.92~1.02; risk ratio 0.96, 
95% CI 0.89~1.04). CONCLUSIONS: These ﬁndings suggest that calcium channel 
blockers decrease the risk of stroke more effectively than other treatments in patients 
with hypertension. Moreover, when calcium channel blockers were compared with 
new antihypertensive drugs they demonstrated similar reductions in cardiovascular 
morbidity and mortality.
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OBJECTIVES: To estimate the relative efﬁcacy of clopidogrel versus low-dose aspirin 
plus extended-release dipyridamole (ASAERDP) in preventing serious vascular events 
among stroke patients. Additionally, to test whether a network meta-analysis (NMA) 
can give reliable estimates of treatments’ relative efﬁcacy in the absence of direct evi-
dence. METHODS: A systematic literature review was conducted in EMBASE and 
MEDLINE to identify randomized controlled trial (RCT) evidence on the endpoint 
“serious vascular events” (including myocardial infarction, stroke and vascular death). 
A NMA with ﬁxed effects was ﬁtted to the data using Winbugs. The NMA was ﬁrst 
run on indirect evidence only (NMA_indirect), and these results were compared with 
results from a NMA including direct and indirect evidence (NMA_all). RESULTS: 
Three RCTs were identiﬁed (ESPS2, ESPRIT, CAPRIE) comparing clopidogrel or 
ASAERDP with aspirin; one RCT (PRoFESS) provided direct evidence, two RCTs 
(CHARISMA and MATCH) provided additional data on clopidogrel through the link 
with aspirinclopidogrel. Furthermore, one meta-analysis (ATC) compared the efﬁ-
cacy of different aspirin dosages; this was added in the network to link the aspirin 
arms which differed in dosage. The odds ratio (OR) of ASAERDP versus clopidogrel 
for NMA_indirect was 1.15 (0.95:1.37); PRoFESS reported 0.99 (0.92:1.07); and 
NMA_all resulted in 1.02 (0.95:1.10). All analyses have OR close to “1” and conﬁ-
dence intervals overlapping “1”. The point estimate of PRoFESS is within the conﬁ-
dence bounds of NMA_indirect, but the OR from these analyses are in opposite 
directions. The conﬁdence interval of NMA_all tightens when adding PRoFESS into 
the network. CONCLUSIONS: The results of the analysis indicate that clopidogrel 
and ASAERDP are of equivalent efﬁcacy in preventing secondary serious vascular 
events. Furthermore, in the absence of direct evidence, statistical techniques such as 
NMA can provide a reasonable estimate of relative efﬁcacy.
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OBJECTIVES: To explore the effectiveness of combination regimens containing 
Angiotensin Receptor Blockers (ARBs) compared to those containing ACE Inhibitors 
(ACEIs) in reaching target blood pressure (BP) in a real-world setting. METHODS: 
Records from a longitudinal population-based database of more than 170,000 patients 
in over 53 family practice clinics in southwestern Ontario, Canada were analyzed. 
These records contained chart-abstracted information such as visit diagnosis, BP, 
medications and consultation notes. The records from adult non-diabetic patients who 
were diagnosed with hypertension and were initiated on combination therapy in 2005 
and continued on the combination for at least 9 months were included. Hypertension 
was deﬁned as a BP exceeding 140/90 mmHg, chart entry of a diagnosis of hyperten-
sion, or use of anti-hypertensive medication. The proportions of patients reaching 
target BP (BP less than 140/90 mmHg) were recorded. Due to the well known com-
parable safety proﬁle of the compounds, a safety analysis was not performed. 
RESULTS: A total of 6160 patients were treated with dual combinations containing 
an ARB or an ACEI. In patients treated with at least one ARB, 39% reached target 
BP compared to 31% of those not treated with an ARB (p  0.004). When comparing 
combinations with HCTZ, 35% and 30% of those on ARB and ACEI, respectively, 
reached target BP (p  0.006). Within the patients treated with an ARB either in dual 
or tri-therapy, 48% of patients irbesartan reached target BP when the ARB was irbe-
sartan compared to 42% for losartan or valsartan (p  0.001 for both), and 41% for 
candesartan (p  0.001). CONCLUSIONS: In a real-world setting, a greater propor-
tion of hypertensive patients treated with a combination containing an ARB reached 
target BP than those treated with a combination not containing an ARB. Within the 
ARB class, a greater proportion of patients treated with a combination containing 
irbesartan reached target BP.
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OBJECTIVES: The objective of this study was to assess diagnostic efﬁcacy and safety 
of implantable loop recorder (ILR) in detection of causes of unexplained or/and recur-
rent syncopes in comparison with conventional diagnostic testing (CDT). METHODS: 
Comparison was based on a systematic review, carried out according to guidelines 
published by Medical Services Advisory Committee (MSAC) and the Agency for 
Health Technology Assessment in Poland. The most important medical databases 
(MEDLINE, EMBASE, CENTRAL) were searched. Two reviewers independently 
selected trials, extracted data and assessed their quality (using QUADAS scale). Quan-
titative analysis was impossible because of heterogeneity between trials with respect 
to baseline characteristic of participants and meaningful differences in duration of 
observation periods between ILR and CDT groups. Assessing speciﬁcity and sensitivity 
of ILR was not possible due to lack of reference tests in included studies. Therefore 
only qualitative analysis was performed. RESULTS: The results of 4 randomized 
control trial (RCTs) and 32 case series (CSs) were included in the analysis. In 3 RCTs 
syndromes (syncope and palpitations) were observed in 42–77% of patients in ILR 
group and 33–73% in CDT group. Determining diagnosis of syncope was successful 
in 33–73% patients with ILR and in 4–21% patients diagnosed by CDT. The results 
from 1 RCT indicate that ILR can prevent implantation of pacemaker in 88% patients 
with unexplained syncope. In CSs syncope and presyncope were reported in 12%-
100% patients and ILR enable to obtain diagnosis in 62,5–100% patients. Medical 
incidents occurred in 2% of patients in CSs. Infections in the insertion site and injuries 
caused by syncope were most commonly reported. Malfunction of the device occurred 
in 51 patients in CSs and 1 patient in RCT. CONCLUSIONS: ILR implantation is 
efﬁcient and safe diagnostic strategy for determine the cause of unexplained or/and 
recurrent syncope.
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OBJECTIVES: This retrospective analysis of a primary care database compares the 
effectiveness of Angiotensin Receptor Blockers (ARBs) used in monotherapy to ACE 
Inhibitors (ACEIs), Calcium Channel Blockers (CCBs), Beta-Blockers (BBs) and diuret-
ics in reaching target blood pressure (BP). METHODS: Records from a longitudinal 
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population-based database of more than 170,000 patients in over 53 family practice 
clinics in southwestern Ontario, Canada were analyzed. These records contained 
chart-abstracted information such as visit diagnosis, BP, medications and consultation 
notes. The records from 10,120 adult non-diabetic patients who were diagnosed with 
hypertension and were initiated on treatment in 2005 and continued on monotherapy 
for at least 9 months were included. Hypertension was deﬁned as a BP exceeding 
140/90 mmHg, chart entry of a diagnosis of hypertension, or use of anti-hypertensive 
medication. The proportions of patients reaching target BP (BP less than 140/90 mmHg) 
were recorded. Due to the well known safety proﬁle of the compounds, a safety analy-
sis was not performed. RESULTS: After 9 months of treatment with monotherapy, 
the proportions of patients reaching target BP are as follows: 28% on ARBs compared 
to 27% on ACEIs (p  0.05), 26% on CCBs (p  0.05), 21% on BBs (p  0.002), and 
19% on diuretics (p  0.001). Within the ARB class, the proportions of patients 
reaching target BP are as follows: 38% on irbesartan compared to 32% on losartan 
(p  0.01), 9% on valsartan (p  0.001) and 25% on candesartan (p  0.001). CON-
CLUSIONS: In a real-world setting, similar proportion of patients treated with ARBs, 
ACEIs and CCBs monotherapy reached target blood pressure. Amongst the ARBs, a 
greater proportion of irbesartan-treated patients reached target BP. This analysis also 
shows that less than half of the patients treated with monotherapy reach target BP 
supporting the need for combination therapy in the management of hypertension in 
some patients.
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OBJECTIVES: To describe the methodology of a systematic review and meta-analysis          
evaluating the efﬁcacy and safety of anti-arrhythmic drugs (AADs) in the treatment 
of atrial ﬁbrillation (AF). Outcomes of interest included AF recurrence, cardiovascular 
(CV) morbidity, all-cause mortality, discontinuations, serious adverse events (SAE), 
persistence/compliance and health related quality of life (HRQoL). METHODS: Elec-
tronic databases (Cochrane Library, Medline, EMBASE; accessed March 2009) and 
manual bibliographic searches were conducted to identify relevant randomised clinical 
trials (RCTs). Comparators of interest included all AADs, rate and rhythm strategies 
or ablation in comparison with AADs. In addition to dronedarone, the primary AADs 
of interest were restricted to Class IC (ﬂecainide and propafenone) and Class III 
(amiodarone and sotalol). Relevant data were extracted by two independent reviewers. 
Data were analysed on an intention-to-treat basis and meta-analysis performed using 
the Peto odds ratio (OR)/ﬁxed-effect model. The Bucher method was employed for 
indirect comparisons. Direct comparisons and/or indirect comparisons via non-active 
control were conducted where appropriate, in relation to the outcomes of interest. 
RESULTS: In total, 145 separate publications met the pre-deﬁned inclusion criteria          
and were included in the systematic review. Of these, 71 were related to one of the 
ﬁve AADs of primary interest and were analysed. SAEs were reported in 24 pub-
lications, AF recurrence in 44, all-cause mortality in 52 and discontinuations in 62. 
Data relating to other morbidity outcomes such as hospitalisations or to persistence/
compliance and HRQoL were very limited; therefore, meta-analyses were not possible. 
These ﬁndings are consistent with results of a previous Cochrane review (2007). 
CONCLUSIONS: Based on the results of this current systematic review, limited meta-          
analyses were possible. The majority of studies were designed to assess AF recurrence 
only; therefore, few publications assessed relevant clinical markers of AF progression 
or complications such as CV morbidity.
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AND CARDIOVASCULAR MORTALITY IN ATRIAL FIBRILLATION 
PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Mitchell S1, Orme M1, Eckert L2, Reynolds M3
1Abacus International, Bicester, UK, 2Sanoﬁ-Aventis, Paris, France, 3Beth Israel Deaconess 
Medical Center, Boston, MA, USA
OBJECTIVES: Atrial ﬁbrillation (AF) is a potentially life-threatening arrhythmia. 
After restoration of a normal sinus rhythm, AF recurrence may be prevented with 
anti-arrhythmic drugs (AADs). The objective of this review was to evaluate the efﬁcacy     
of a novel AAD (dronedarone) and existing AADs with respect to mortality outcomes. 
METHODS: A systematic literature review was conducted of randomised clinical trials          
(RCTs) investigating the use of AADs in patients with AF. All-cause mortality and 
CV mortality data were extracted. Direct and indirect comparisons adopted an inten-
tion-to-treat basis using Peto odds ratios (OR) with a ﬁxed effect or Bucher model, 
respectively. RESULTS: The majority of published data considered dronedarone,       
amiodarone, sotalol, ﬂecainide or propafenone (32 publications). Peto ORs for all-
cause mortality at 12 months with 95% conﬁdence intervals (CI) for direct and indi-
rect comparisons via non-active control were calculated. In comparisons with 
non-active control, the risks of all-cause mortality were as follows: a signiﬁcant 
increase with sotalol (OR 2.72 [1.16, 6.38]); an increased trend with amiodarone and 
ﬂecainide, and a decreased trend, with a narrow CI, with dronedarone (OR 0.85 [0.66, 
1.09]). Indirect comparison demonstrated that dronedarone was associated with lower 
odds of all-cause mortality; this reached statistical signiﬁcance versus sotalol (OR 3.2 
[1.32, 7.78]). Indirect analysis of amiodarone versus dronedarone (OR 2.38 [0.80, 
7.07]) is consistent with the head-to-head DIONYSOS study (calculated OR 2.32 
[0.52, 10.32]). In both indirect and direct analyses, CIs for propafenone were too wide 
to interpret the results. Only one publication reported CV mortality data and this 
considered dronedarone. Therefore, meta-analyses were not possible. CONCLU-
SIONS: Clinical trial CV mortality data are limited. All-cause mortality does not           
appear to be signiﬁcantly reduced via the use of AADs. Despite this, the novel AAD, 
dronedarone, was associated with lower all-cause mortality risk than those observed 
with existing AADs or non-active control.
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OBJECTIVES: To explore variation in management of acute coronary syndromes 
(ACS), the commonest cardiac cause of hospital admission, and to measure quality of 
life (QoL) with the EQ-5D health state index at discharge. METHODS: A prospective, 
international, observational study recruited ACS patients undergoing percutaneous 
coronary intervention (PCI), April—November 2008, capturing practice patterns, 
resource use and QoL. RESULTS: 496 eligible ACS-PCI patients, 56% with unstable 
angina or non-ST-elevation MI (UA/NSTEMI) and 44% ST-elevation MI (STEMI) 
from Sweden (240), Finland (104), Norway (78) and Denmark (74) were included. 
The median age was 64 years (IQR: 56–72), 75% were male. 84% of patients got an 
aspirin loading dose (median 300 mg) and 95 % got clopidogrel (41% received 
a300 mg, 59% received 600 mg). Admission and discharge medications were: aspirin 
35 and 97%, clopidogrel 10 and 98%, statins 33 and 89%, beta-blockers 35 and 
83%. At admission 32% of patients used an ACE inhibitor, and there was some 
variation at discharge: Sweden and Finland: 73%, Norway 45%, Denmark 37%. 
Almost all patients (97%) had stents implanted. In Sweden 80%, in Finland 68%, in 
Norway 64%, and in Denmark 6% of patients got bare metal stents (BMS) only. Time 
from hospital admission to PCI: median 1 day (IQR 1–3 days) for UA/NSTEMI 
patients, (81% 3 days or less; Sweden-90%, Finland-82%, Norway-71%, Denmark-
57%). Almost all (97%) STEMI patients were treated within one day from admission. 
Total stay was median 4 days (IQR: 3–6) for both cohorts. The median (IQR) QoL 
at hospital discharge was overall: 0.85 (0.69–1.00), Sweden: 0.85 (0.73–1.00), 
Norway: 0.80 (0.69–1.00), Denmark: 0.87 (0.69–1.00), Finland: no data available. 
CONCLUSIONS: The use of pharmacotherapy in the Nordic countries was high. 
There was substantial variation in management of ACS patients for use of BMS. The 
QoL of patients at discharge was high in all countries.
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OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual 
antiplatelet therapy for 12 months for all patients with acute coronary syndrome 
(ACS). Here we describe the 12-month antiplatelet treatment patterns in ACS patients 
undergoing percutaneous coronary intervention (PCI), and explore variations between 
three European countries. METHODS: The Antiplatelet Treatment Observational 
Registry (APTOR) is a prospective, international observational study that recruited 
ACS patients undergoing PCI in 2007–08, capturing practice patterns, resource use 
and QoL. RESULTS: A total of 1525 ACS-PCI patients were recruited: 38% patients 
presented with ST-elevation myocardial infarction (STEMI), 37% with non-ST eleva-
tion MI (NSTEMI), and 25% with unstable angina (UA). Follow-up data up to 12 
months are available for a total of 1335 (88%) patients. 97% of STEMI patients and 
93% of UA/NSTEMI patients reported using clopidogrel and aspirin after hospital 
discharge; overall clopidogrel use was 94% at discharge, 93% at 30 days, 78% at 6 
months, and 71% at 12 months. Dual clopidogrel and aspirin use at 12 months was 
overall: France 73%, Spain 69%, UK 63%; for STEMI patients, it was: France 74%, 
Spain 66%, UK 61%; for UA/NSTEMI patients: France 72%, Spain 71%, UK 64%; 
for patients with at least one drug eluting stent (DES): France 82%, Spain 82%, UK 
81%; for patients with bare metal stent (BMS) only: France 68%, Spain 38%, UK 
52%. CONCLUSIONS: These prospective data show some variations in the use of 
antiplatelet therapy between three European countries. While in patients with DES, 
one year use of dual oral antiplatelet therapy was similar across countries, in patients 
receiving a BMS only there was considerable variation between the countries. Anti-
platelet prescription cards should be considered.
